Accolade (ACCD) Scheduled to Post Quarterly Earnings on Thursday

Accolade (NASDAQ:ACCD) will issue its quarterly earnings data after the market closes on Thursday, April 25th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Accolade Trading Up 3.6 %

Shares of ACCD stock opened at $8.70 on Thursday. Accolade has a fifty-two week low of $6.33 and a fifty-two week high of $17.00. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.35 and a current ratio of 2.35. The stock has a 50 day simple moving average of $10.24 and a two-hundred day simple moving average of $9.93. The company has a market cap of $673.45 million, a P/E ratio of -5.27 and a beta of 2.08.

Wall Street Analyst Weigh In

ACCD has been the topic of a number of research reports. Barclays began coverage on shares of Accolade in a research report on Wednesday, January 3rd. They set an “equal weight” rating and a $13.00 target price on the stock. Stifel Nicolaus decreased their target price on Accolade from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, January 4th. Truist Financial raised their price objective on Accolade from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, January 9th. Wells Fargo & Company upped their target price on Accolade from $10.00 to $12.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 9th. Finally, Raymond James lifted their price target on shares of Accolade from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Tuesday, January 9th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, Accolade has a consensus rating of “Moderate Buy” and a consensus target price of $15.67.

Hedge Funds Weigh In On Accolade

Several institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC purchased a new position in shares of Accolade in the second quarter worth about $169,000. State of Wisconsin Investment Board grew its stake in Accolade by 100.9% in the 4th quarter. State of Wisconsin Investment Board now owns 21,663 shares of the company’s stock valued at $169,000 after buying an additional 10,882 shares in the last quarter. Delphia USA Inc. bought a new stake in Accolade during the 1st quarter valued at $163,000. Walleye Capital LLC purchased a new stake in shares of Accolade during the second quarter worth $159,000. Finally, Hsbc Holdings PLC boosted its holdings in shares of Accolade by 24.8% in the third quarter. Hsbc Holdings PLC now owns 14,721 shares of the company’s stock worth $156,000 after acquiring an additional 2,926 shares during the period. Hedge funds and other institutional investors own 84.99% of the company’s stock.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.